BIOCRYST PHARMACEUTICALS, INC. Nontrade Receivables, Current
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Nontrade Receivables, Current of $2.37 million as of 2013-09-30, per its 10-Q filed 2013-11-08.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:NontradeReceivablesCurrent · last filed 2013-11-08
- 2013-09-30: Nontrade Receivables, Current $2.37M.
- 2013-06-30: Nontrade Receivables, Current $1.02M.
- 2013-03-31: Nontrade Receivables, Current $4.33M.
- 2012-12-31: Nontrade Receivables, Current $4.56M.
| Period end | Nontrade Receivables, Current |
|---|---|
| 2013-09-30 | $2.37M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $1.02M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $4.33M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $4.56M 10-Q · filed 2013-11-08 |
| 2012-09-30 | $3.77M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $5.08M 10-Q · filed 2012-08-08 |
| 2011-12-31 | $5.83M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |